{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:46:07Z","timestamp":1761061567084,"version":"3.37.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12350-021-02880-8","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T18:21:47Z","timestamp":1639765307000},"page":"3111-3114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2433","authenticated-orcid":false,"given":"Robert J.H.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-021-02880-8_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of (99m)Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02880-8_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02880-8_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-021-02880-8_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02880-8_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1007\/s12350-021-02880-8_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1007\/s12350-021-02880-8_bib7","doi-asserted-by":"crossref","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging 2021;14:e000029.","DOI":"10.1161\/HCI.0000000000000029"},{"key":"10.1007\/s12350-021-02880-8_bib8","first-page":"137","article-title":"Volumetric evaluation of 99mTc-pyrophosphate SPECT\/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters","volume":"62","author":"Watanabe","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02880-8_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02880-8_bib10","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02880-8_bib11","article-title":"Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis","author":"Roshankar","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02880-8_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-021-02880-8_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13550-021-00828-0","article-title":"Quantitative SPECT\/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis","volume":"11","author":"Ben-Haim","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1007\/s12350-021-02880-8_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/s40658-020-00342-7","article-title":"Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT","author":"Ren","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1007\/s12350-021-02880-8_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis: A novel imaging biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02880-8_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41824-018-0035-1","article-title":"Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population","volume":"2","author":"Ramsay","year":"2018","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1007\/s12350-021-02880-8_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2967\/jnumed.112.111476","article-title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","volume":"54","author":"Bailey","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-021-02880-8_bib18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02880-8_bib19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1007\/s12350-021-02880-8_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-021-02880-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123006852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123006852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:43:44Z","timestamp":1735573424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123006852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1071358123006852"],"URL":"https:\/\/doi.org\/10.1007\/s12350-021-02880-8","relation":{},"ISSN":["1071-3581"],"issn-type":[{"type":"print","value":"1071-3581"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-021-02880-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}